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ABSTRACT
Aims To describe baseline characteristics and visual
outcome for eyes treated with ranibizumab for diabetic
macular oedema (DMO) from a multicentre database.
Methods Structured clinical data were anonymised
and extracted from an electronic medical record from
19 participating UK centres: age at ﬁrst injection,
ETDRS visual acuity (VA), number of injections, ETDRS
diabetic retinopathy (DR) and maculopathy grade at
baseline and visits. The main outcomes were change in
mean VA from baseline, number of injections and
clinic visits and characteristics affecting VA change and
DR grade.
Results Data from 12 989 clinic visits was collated
from baseline and follow-up for 3103 eyes. Mean age at
ﬁrst treatment was 66 years. Mean VA (letters) for eyes
followed at least 2 years was 51.1 (SD=19.3) at
baseline, 54.2 (SD: 18.6) and 52.5 (SD: 19.4) at 1 and
2 years, respectively. Mean visual gain was ﬁve letters.
The proportion of eyes with VA of 72 letters or better
was 25% (baseline) and 33% (1 year) for treatment
naïve eyes. Eyes followed for at least 6 months received
a mean of 3.3 injections over a mean of 6.9 outpatient
visits in 1 year.
Conclusions In a large cohort of eyes with DMO
treated with ranibizumab injections in the UK, 33% of
patients achieved better than or equal to 6/12 in the
treated eye at 12 months compared with 25% at
baseline. The mean visual gain was ﬁve letters. Eyes
with excellent VA at baseline maintain good vision at
18 months.
Q1
INTRODUCTION
Intravitreal injections of ranibizumab are an estab-
lished therapy to treat a sight-threatening complica-
tion of diabetic retinopathy (DR), diabetic macular
oedema (DMO). In the UK, the second highest
annual National Health Service (NHS) expenditure
for any single drug is for ranibizumab (£244
million).1 Clinical practice was initially informed by
pivotal clinical trials,2–7 which demonstrated that
ranibizumab prevents central vision loss and
improves mean visual acuity (VA), when given at
monthly or according to pro re nata intervals in
eyes with DMO.
In the UK, the National Institute for Health and
Care Excellence approved the use of ranibizumab
for DMO in February 2013, leading to universal
availability of this drug in the NHS, but only if the
central retinal thickness was 400 microns or more.
Delivering the therapy with a recommendation of
monthly assessment and then retreatment for
‘active’ disease makes substantial demands on
healthcare services, funding authorities and
patients. A recent review of the use of ranibizumab
for any indication shows a more than twofold geo-
graphic variation in usage across England.8 The
intervention is costly and intensive, so it is import-
ant to understand what visual outcomes are
achieved and how clinical trial results ‘translate’
into clinical practice in the ‘real world’.
Clinical trials are limited by entry criteria, for
example, excluding patients with uncontrolled
medical conditions or severe DR, and have a
limited number of trial subjects. In particular for
DMO, the haemoglobin A1c and blood pressure in
pivotal trials can be substantially different from
‘real-world’ patients,9 10 although a recent study
suggests this may not affect outcomes of treat-
ment.11 Electronic medical record (EMR) systems,
if well-designed, offer more complete, prospective,
real-time data collection as a by-product of routine
care. They can be designed to mandate capture of a
deﬁned minimum dataset and allow the collection
of more enriched datasets. The NHS Connecting
for Health’s ‘Do Once and Share’ programme has
deﬁned EMR datasets in ophthalmology including:
diabetic eye disease, the cataract national dataset
and the glaucoma dataset.12
This study aims to report the visual outcome and
deﬁne benchmark standards of care for patients
treated with ranibizumab for DMO at a large
number of the UK centres.
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METHODS
Ethical approval
The lead clinician and Caldicott Guardian at each centre gave
written approval for extraction of anonymised data. The study
protocol was approved by the head of research governance at the
lead clinical centre. This study was conducted in accordance with
the Declaration of Helsinki and the UK Data Protection Act.
Data collection
Anonymised data were remotely extracted from 19 centres using
the same EMR system (Medisoft Ophthalmology, Medisoft,
Leeds, UK) in November 2014. Each site is the only NHS pro-
vider of DMO care to their local population and very few
patients switch between providers or access care privately. Data
were extracted through the EMR compulsory DR structured
assessment module (see online supplementary ﬁle for detailed
explanation). Demographic data were extracted from the hospi-
tal’s patient administration system to the EMR.
All patients had data extracted from the time of their ﬁrst DR
structured assessment entry onto the EMR, including the data from
the time of their ﬁrst injection of ranibizumab up to the date of their
last clinical entry before the data extraction on 26 November 2014.
Missing data
The EMR data extraction does not record values on visits where
the EMR was not used, so no missing value substitutions were per-
formed. The only exception to this rule was baseline VA. Some
treatment centres operate ‘2 stop’ or ‘injection only’ clinics, where
treatment is given without measuring vision. Six centres have over
10% of injections without recording a VA measurement on the
same day. For these services, the baseline VA was taken from the
prior assessment visit if within 4 weeks of the injection date. This
was therefore not missing data per se but reﬂects variation in treat-
ment delivery. Therefore, data on number of visits represent a nor-
malised value to allow standardised comparison between centres,
rather than the precise number of attendances by the patient.
Analyses of all patients initiated into the study were compared
with the cohort of patients that completed follow-up.
Analysis
The primary analysis was restricted to treatment-naïve eyes
undergoing ranibizumab therapy as the only treatment for
DMO during the follow-up period. Secondary analyses of eyes
with other treatments prior to undergoing intravitreal ranibizu-
mab therapy, or who were treated with combination therapy,
were also undertaken. Eyes that had cataract surgery within
3 months of their ﬁrst ranibizumab injection or during the
period of follow-up were excluded.
Eyes were assigned to two groups according to their treat-
ment history and were analysed separately. Group 1 eyes were
treatment naïve at baseline for any treatment for DMO (includ-
ing intravitreal injections of any drug, macular laser treatments
and vitrectomy), but could have had previous peripheral scatter
retinal laser at the time of their ﬁrst injection of ranibizumab
and were managed solely with ranibizumab during the course of
follow-up until the end of the data extraction period. DMO
group 2 patients had received other treatments for diabetic
macular disease prior to their ﬁrst injection of ranibizumab.
RESULTS
Participants
Data were extracted on 123 968 eyes of 61 984 patients with
DR. There were 33 967 male patients and 28 002 female
patients (in 15 cases, gender was not recorded).
The 19 UK hospitals treated a total of 3103 eyes from 2416
patients, who received 15 537 ranibizumab injections for
CIDMO during 12 989 clinic visits. No patients in this dataset
received ranibizumab for non-CIDMO. Of these, 28% (n=687)
patients received bilateral treatments.
The 19 sites entered their ﬁrst DMO ranibizumab treatment
episodes into the EMR systems during the following years:
2008 (n=4 sites), 2009 (n=1), 2010 (n=5), 2011 (n=5), 2012
(n=3), 2014 (n=1). The ﬁrst recorded ranibizumab injection
for DMO was dated 10 June 2008.
The mean age (at the time of the ﬁrst DMO injection) was
66 years (SD 13 years). The female to male ratio was 1.45:1
(1430/986 patients). There were 268 (16% of the patients with
a known diabetic status) patients with type 1 diabetes mellitus.
There were 1380 patients (84%) recorded with type 2 diabetes
mellitus. The rate of endophthalmitis was 0.015%.
Treatment history
There were 1584 treatment-naïve eyes in group 1. Group 2 had
1471 eyes (1112 macular laser treatments, 77 vitrectomies, 332
bevacizumab, 212 with triamcinolone). Of the patients in group
2 who had received previous treatment, the median (IQR) time
between the ﬁrst ranibizumab injection and the previous diabetic
macular treatment was 0.6 (0.2, 1.2) years.
Visual acuity
About 34.1% of BCVA Q3
¶
tests were converted by the EMR software
at source from Snellen to letter score equivalent. The rest were
recorded as ETDRS letters. Baseline VA is shown in online
supplementary figure S1 for all treatment groups. There was a mean
gain of ﬁve letters at 12 months when both groups were analysed.
Treatment-naïve eyes
The proportion of eyes with VA of 20/40 or better (72 or more
letters) in the better-seeing eye was 25% at baseline, 33% at
year 1, 24% at year 2. A more complete understanding of the
change in vision is obtained by plots of VA at different time
points (ﬁgure 1) demonstrating mean, and SD of the data strati-
ﬁed by starting VA.
Figure 2 shows the association of number of injections and
VA difference between the last and ﬁrst injection to the baseline
VA for treatment-naïve eyes. There was no signiﬁcant association
between the number of injections and baseline VA, but the VA
difference is negatively associated with the baseline VA.
Table 1 shows the visual change and number of injections
from baseline; 17.3% of eyes gained at least 15 letters. Sixty per
cent of eyes were in the 0–15 letter change from baseline.
The baseline DR grade within 4 months of the ﬁrst injection
did not seem to inﬂuence the average VA outcomes (see online
supplementary ﬁgure S2) in the ﬁrst year of treatment.
Online supplementary ﬁgure S3 highlights the change in
mean VA between patients with up to 1 year of follow-up
(n=1136) and those with >1 year of follow-up (n=363).
Effect of baseline characteristics on VA change
The treatment effect, quantiﬁed as the VA difference between
the last and ﬁrst injection, is negatively associated with baseline
acuity (ﬁgure 2) for treatment-naïve eyes, there was a ‘ceiling
effect’ for those with better vision, who showed a reduced
visual gain compared with baseline. Of note, the VA change
from the baseline for eyes receiving at least three ranibizumab
treatments was stratiﬁed by the baseline VA of 70–100 letters
(548 eyes), 55–69 letters (813 eyes), 40–54 letters (422 eyes)
and 0–39 letters (403 eyes) and is illustrated in ﬁgure 1. Eyes in
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the 55–70 letter group gained a mean of 5 letters at month 12
but not at month 18, and in the 40–55 letter group gained a
mean of 10 letters, which was maintained at month 12 and at
month 18. The poor baseline VA group (0–40 letters) gained a
mean of 12 letters at month 12, but the VA results from 12 to
18 months, while showing mean gains, were highly variable.
Figure 3 shows mean VA versus months since the ﬁrst injection.
Number of injections and visits
The frequency of ranibizumab injections at various treatment
lengths is shown in online supplementary ﬁgure S4. Eyes
followed-up for at least 6 months received a mean of 3.3 injec-
tions. The mean number of outpatient visits (normalised to
allow comparison of one stop and two stop services as discussed
in the Methods section) in the ﬁrst year of follow-up was 6.9
visits.
DISCUSSION
This study conﬁrms that clinics using EMRs that mandate collec-
tion of nationally agreed datasets can prospectively collect large
volumes of ‘real-life’ outcomes data on patient characteristics,
DMO treatments and visual outcomes that can be rapidly
Figure 1 Visual acuity (VA) change in letters from baseline stratiﬁed by starting vision in ETDRS letter for treatment-naïve eyes (group 1).
Figure 2 The association of the number of injections and visual acuity difference between the last and ﬁrst injection to the baseline visual acuity
for the treatment-naïve eyes.
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extracted for analysis. Data were collected as part of routine
clinical care and form part of the patient’s contemporaneous
clinical care record. One potential weakness of this study is that
some centres used the EMR only for patients receiving injec-
tions and that patients apparently lost to follow-up were in fact
still under review in outpatient clinics. Patients with either very
good or very poor responses to therapy may have been lost to
this dataset in those centres. Key missing data points that repre-
sent areas of inﬂuence in designing care pathways (eg, ethnicity
data, or validated type of diabetes mellitus, VA data on non-
treatment clinic visits) will be important in the future designs of
ophthalmic EMRs.
In this study, there was a mean gain of ﬁve letters at
12 months after initiation of treatment when both
treatment-naïve and previous treatment groups were analysed
together. This is quite disappointing compared with the pivotal
trials,2 3 5–7 9 13–15 which observed a mean gain of 10.6–11.1
letters at 12 months. DMO observations from smaller open-
label prospective, phase IIIb studies such as PRIDE (n=515),
RELIGHT (n=108) and RETAIN (n=332) observed slightly
greater VA acuity gains at >12 months ranging from four to
eight letters.16 17 However, the gain at 12 months is similar to
real-world studies16 18 and within the range from an analysis of
several trials.19
Our ﬁndings from the UK real-world practice may reﬂect the
more chronic nature of the disease in some patients, who had
waited for access to ranibizumab or received other treatments
for DMO prior to national approval; the presence of other
ocular or systemic conditions that may limit the efﬁcacy of treat-
ment that were excluded from clinical trials or undertreatment
and insufﬁcient follow-up visits. It is also worth noting that
patients were only eligible for initiating ranibizumab therapy
when their macular thickness was >400 microns. This imposed
threshold may have resulted in the increased chronicity of
disease in our UK-based cohort. The impact of a longer duration
of DMO and previous macular laser on reducing VA gains has
been suggested in the outcomes from clinical trials.5
Furthermore, our ﬁndings may also reﬂect service delivery issues
—fewer injections per eye, longer intervals between injections
than clinically indicated, longer delays before initiation of treat-
ment or recommencement of treatment after a recurrence, vari-
ability in interpretation of retreatment criteria or stopping and
starting criteria.
Nonetheless, analysis of this dataset does highlight some
encouraging ﬁndings. Figure 1 shows that eyes with excellent
starting VA (70–100 letters) at baseline maintained good mean
VA throughout the 18 months follow-up, although showed a
slight negative gain (−2 letters at 18 months). This emphasises
the ceiling effect of visual gain as an outcome measure and indi-
cates that gain is not a good measure of the quality of care. In
contrast, eyes with worse starting acuity achieved a greater gain
in acuity. However, the ﬁnal VA achieved in these patients,
which is often the most important outcome for the patient, was
not as good as those with a good baseline VA. This has been
similarly observed in other diseases, such as age-related macular
degeneration treated with ranibizumab20 and in another study
of DMO outcomes.19
There were 373 eyes in the worst VA group and the reasons
for the variability in vision in the second year of follow-up
warrant further study. It is possible that the ﬁrst-year VA results
Table 1Q2 Visual change and number of injections from baseline for eyes receiving at least three injections and with a baseline visual acuity
recorded within 4 weeks of the first injection, vision change (letters) from baseline and the number of injections (SD) during the whole period of
follow-up.
Visual acuity letters from baseline Loss 30 or more Loss 15–29 Loss 1–14 Stable/gain 0–14 Gain 15–29 Gain 30 or more
Number of eyes (total=2292) (%) 30 (1.3) 0 490 (21.4) 1375 (60.0) 318 (13.9) 79 (3.4)
Number of injections (SD) 4.6 (2.6) 0 5.4 (2.8) 5.3 (2.9) 6.1 (3.6) 5.8 (3.3)
Visual change and number of injections from baseline for eyes receiving at least three injections and with a baseline visual acuity recorded within 4 weeks of the first injection, vision
change (letters) from baseline and the number of injections (SD) during the whole period of follow-up.
Figure 3 Upper: visual acuity (mean
and SD) versus months since the ﬁrst
injection for all treatment groups
(upper graph) and the number of eyes
contributing to each data point
(lower). Lower: number of eyes treated
plotted against months from ﬁrst
injection of ranibizumab for eyes with
a baseline visual acuity recorded
within 1-month of the ﬁrst injection.
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reﬂect resolution of macular oedema and the second-year results
reﬂect other ocular pathologies, such diabetic macular ischaemia
or poor glycaemic control. A recent study suggested that the
level of diabetic control may not inﬂuence VA outcomes.9
Role for benchmarking standards
‘Translating’ the results of clinical trials into real-world clinical
settings is a well-recognised problem that well-designed EMR
systems can inform. In order to understand how well we are
delivering care, we need to understand what can be achieved in
unselected patient populations and how they differ from clinical
trials.
This study represents the visual outcomes achieved in routine
clinical practice in the UK prior to 2014 and provides a ‘real-
world’ benchmark to compare local outcomes. It is important
to note, however, that these results were obtained with fewer
injections and fewer clinical visits than the pivotal studies.
An important benchmark for visual function is the proportion
of patients who achieve 20/40 or better, which approximates
the UK driving standard threshold. In this study, 33% of
patients achieved better than or equal to 20/40 in the treated
eye at 12 months. In the RISE and RIDE trials at baseline, this
proportion of eyes was 19.7% and 19.2% in the control arms
and 19.2% and 19.7% in the 0.5 mg ranibizumab treatment
arms. At 12 months, this proportion of eyes was 34.6% and
37.8% in the control/crossover arms and 62.2% and 63.2%21 in
the 0.5 mg ranibizumab arms.
Another important benchmark is the stability of vision after
the maximum VA gained. Vision stability is thought to be an
important outcome in other studies7 21 and is clearly of primary
importance to patients. We suggest that VA stability is an
important measure of the quality of service delivery. It is inde-
pendent of baseline acuity and may therefore be used as a
metric for comparisons between different population groups. In
our cohort, VA gains at 6 months were stable at 18 months,
except the group with the worst starting VA.
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